News & Events » Media Stories
Ophthalmology Times—July 13, 2011—AMD Treatment Results Encouraging
Friday, 15 July 2011
|
The first dose level of a novel gene-based treatment (RetinoStat, Oxford BioMedica) for neovascular age-related macular degeneration (AMD) is safe and well-tolerated at 1 month following treatment, the company has announced. Read the full article >
|









![Casting A Wide Net[work] | Presenting the interactive Foundation Fighting Blindness 2012 Annual Report 2012 Annual Report banner](https://www.blindness.org/images/banners/annual_report_box.jpg)


